WHAT: Scientists from across the nation will gather June 3-4 to discuss what is known about sickle cell trait and the potential health implications related to this genetic blood condition. "Framing the Research Agenda for Sickle Cell Trait" will examine the ethical, legal, social, and public health impacts of the blood condition.
The two-day workshop is sponsored by the National Heart, Lung, and Blood Institute (NHLBI), part of the National Institutes of Health, and the Advisory Committee of Blood Safety and Availability in the Office of Public Health and Science, U.S. Department of Health and Human Services.
WHEN: The free workshop, which is open to the public, runs from 8:30 a.m. to 5 p.m. on Thursday, June 3, and from 8 a.m. to 1 p.m. on Friday, June 4. NHLBI Acting Director Susan B. Shurin, M.D., a hematologist, will provide opening remarks.
Workshop highlights include:
WHERE: Natcher Auditorium ((Building 45) on the NIH campus, Bethesda, MD.
WHY: About 2.5 million Americans have sickle cell trait, which means they carry one copy of an altered hemoglobin gene. Hemoglobin transports oxygen in red blood cells throughout the body. In most cases, people who have sickle cell trait have no symptoms and lead normal lives.
Sickle cell trait is not the same as sickle cell disease. Some people who inherit two copies of the altered hemoglobin gene have sickle cell disease, a condition with misshapen red blood cells that leads to the development of serious health problems. Sickle cell disease, which affects about 70,000 Americans, is most common in people of African, Middle Eastern, Mediterranean, Central and South American and Asian Indian origin or descent.
|Contact: NHLBI Communications Office|
NIH/National Heart, Lung and Blood Institute